The policy specifies an operational list of contraindications that, if present, may lead to denial of medical necessity for a planned tandem hematopoietic cell transplant. Key laboratory and clinical thresholds include: bilirubin > 2 mg/dL (hepatic dysfunction); INR > 1.6 (unless the member is on oral anticoagulants); and cardiac ejection fraction (EF) < 45% on MUGA or echocardiogram. Pulmonary criteria that can disqualify a candidate include FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted. Performance-status thresholds that can disqualify are Karnofsky/Lansky < 70% or ECOG > 2, and uncontrolled or disseminated infection is also a contraindication.
The policy also operationalizes a broader set of clinical states that may preclude approval: acute liver failure; acute renal failure; septic shock; active extrapulmonary or disseminated infection (including active tuberculosis); progressive cognitive impairment; other severe uncontrolled medical conditions; and substance use. In addition, the revised contraindication framework references renal function limits (GFR below policy-specified thresholds) as exclusionary when documented.
For members with HIV, the policy specifies conditions under which transplantation may still be considered: the member must meet all three HIV-specific acceptance criteria — CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and being currently on effective antiretroviral therapy — otherwise HIV with a detectable viral load is a contraindication.
Operationally, the presence of any of the above-listed contraindications should be documented in the medical record and will be reviewed during prior authorization and coverage verification. Providers should supply relevant laboratory results, imaging reports (e.g., MUGA/echocardiogram, pulmonary function testing), performance-status assessments, and evidence of infection evaluation to demonstrate absence of disqualifying conditions prior to approval.
This contraindication list replaced earlier, broader language and is intended to be applied consistently with clinical judgment, guideline-referenced standards, and any applicable regulatory requirements. When there is uncertainty or the member’s status is borderline, reviewers should confirm that all required documentation and evaluations have been submitted and consider case-by-case review as noted in the policy.